drugset / Trial / NCT05897320
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
Timeline
- Start
- 2023-06-08
- Primary completion
- 2027-07-06
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eptinezumab | Monoclonal antibody | 100 mg | Intravenous |
| Subject | Eptinezumab | Monoclonal antibody | 300 mg | Intravenous |